Article

FDA issues approvable letter for Allergan's Combigan

Washington, DC-The FDA has issued an approvable letter for brimonidine tartrate/timolol maleate ophthalmic solution (Combigan, Allergan Inc.), outlining the remaining conditions that the company must meet to obtain final marketing approval from the agency.

Washington, DC-The FDA has issued an approvable letter for brimonidine tartrate/timolol maleate ophthalmic solution (Combigan, Allergan Inc.), outlining the remaining conditions that the company must meet to obtain final marketing approval from the agency.

The Irvine, CA, company aims to market the solution in the United States as adjunctive or replacement therapy to reduce elevated IOP in patients with glaucoma or ocular hypertension. The drop already is approved and marketed in Europe, Canada, Brazil, and Australia.

“In its approvable letter, the FDA suggested an additional confirmatory study to address certain questions,” said Scott M. Whitcup, MD, Allergan’s executive vice president, research and development. “Allergan already commenced a clinical study at the end of 2005 that addresses the remaining FDA questions.”

The company is committed to working with the FDA on any remaining issues, he said.

The two agents in Combigan, brimonidine tartrate ophthalmic solution 0.2% (Alphagan) and timolol ophthalmic solution 0.5%, a beta blocker, already have been shown to reduce IOP.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
© 2025 MJH Life Sciences

All rights reserved.